Viral inactivation methods for continuous manufacturing of antibodies
This disclosure relates to methods for use in inactivating viruses. The virus inactivation methods are for use in continuous process manufacturing of a biologic such as an antibody, and include separating an eluate using a column, subjecting said eluate to an orthogonal treatment of low pH and detergent simultaneously wherein, the time for viral inactivation is reduced. In addition, the detergent can be added to buffer system in purification process to achieve the same effect. The biologic in each treatment case is retained.
1. A virus inactivation method for use in continuous process manufacturing of a biologic, comprising:
(a) separating an eluate with a biologic and active virus using a column;
(b) subjecting said eluate with said active virus to an orthogonal treatment of low pH, wherein the pH is from 3 to 4, and a Mega-10 non-ionic detergent, wherein Mega-10 is a N-Methylglucamide, simultaneously to inactivate said virus;
wherein the time for viral inactivation of the eluate is reduced as compared to the separate treatment time of the eluate using low pH or the Mega-10 non-ionic detergent, the biologic is retained, wherein the virus comprises enveloped viruses, in a family selected from the group consisting of: Retroviridae, Flaviviridae - , Togaviridae, Coronaviridae, Filoviridae, Rhabdoviridae, Bunyaviridae, Orthomyxoviridae, Paramyxoviridae, Arenaviridae, Hepadnaviridae, Herpesviridae, Baculoviridae and Poxviridae , and the Mega-10 non-ionic detergent concentration is in the range of from 0.05-1%(w/v).
2. The virus inactivation method as recited in claim 1 , wherein the column comprises an affinity column.
3. The virus inactivation method as recited in claim 2 , wherein the affinity column comprises a protein A column.
4. The virus inactivation method as recited in claim 1 , wherein the biologic comprises a protein.
5. The virus inactivation method as recited in claim 1 , wherein the biologic comprises an antibody.
6. The virus inactivation method as recited in claim 1 , wherein the biologic comprises an antibody fragment.
7. The virus inactivation method as recited in claim 1 , wherein the eluate comprises a biologic of 1 to 100 mg/mL (w/v).
8. The virus inactivation method as recited in claim 1 , wherein the virus inactivation time is reduced from 60-120 minutes to 3-4 minutes.
9. The virus inactivation method as recited in claim 1 , wherein the retrovirus-virus comprises, X-MuL V.
10. The virus inactivation method as recited in claim 1 , wherein the Herpesviridae comprises porcine pseudorabies virus (PRV).
11. The virus inactivation method as recited in claim 1 , wherein the virus inactivation method takes place in a temperature range of 2-30° C.